BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 106/6 (Dec) pp. 993-1234
Pages: 1203-1214

BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase

Online Supplementary Material

L. Hu (1), Z. Fan (2), H. Du (3), R. Ni (4), S. Zhang (1), K. Yin (1), J. Ye (1), Y. Zhang (1), X. Wei (2), X. Zhang (5), P. L. Gross (4), S. P. Kunapuli (6), Z. Ding (1)

(1) Key Laboratory of Molecular Medicine, Ministry of Education, and Department of Biochemistry and Molecular Biology, Fudan University Shanghai Medical College, Shanghai, China; (2) Department of Chemistry, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China; (3) College of Science, Beijing University of Chemical Technology, Beijing, China; (4) Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; (5) Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China; (6) Department of Physiology and the Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania, USA


Antithrombotic, Antiplatelet, BF061, PDE inhibitor, P2Y12 receptor antagonist


The addition of phosphodiesterase (PDE) inhibitors has been reported to potentiate the antithrombotic effects of P2Y12 antagonists without increasing bleeding risk. In this study, we report that a potent antiplatelet agent, 2-ethylthio-6-phenethylaminoadenosine (BF061), inhibits platelet activation and thrombosis via P2Y12 antagonism and PDE inhibition. We explored the antiplatelet mechanism of BF061 by measuring cAMP, cGMP levels, PDE activity, and the interaction between ADP and P2Y12 using atomic force microscopy. The antithrombotic effect of BF061 was evaluated in mice using intravital microscopy in FeCl3-induced mesenteric and laser-induced cremasteric arterial thrombosis models. BF061 robustly inhibited platelet aggregation and ATP release induced by multiple platelet agonists via P2Y12 antagonism and PDE inhibition. Interestingly, despite being structurally similar to BF061, P2Y12 receptor antagonist AR-C69931MX had no effect on human platelet PDE. In FeCl3-induced mesenteric arterial thrombosis model, BF061 effectively prevented thrombus formation similarly to clopidogrel; it also reduced thrombus volume in laser-injured cremaster arteriole model. In contrast, BF061 induced dramatically less bleeding at an antithrombotic dose compared to clopidogrel. In summary, we developed a novel antiplatelet and antithrombotic agent targeting both P2Y12 and PDE. Given the prevalence of combined antiplatelet therapy in clinical practice, an antiplatelet agent bearing dual activities may have therapeutic advantage as a potential antithrombotic drug.

You may also be interested in...

A Narrative Systematic Review

P. S. Loewen (1), A. T. Ji (1), A. Kapanen (1), A. McClean (1)

Thromb Haemost 2017 : -


Online Supplementary Material

V. J. Nijenhuis (1), N. Bennaghmouch (1), J.-P. van Kuijk (1), D. Capodanno (2), J. M. ten Berg (1)

Thromb Haemost 2015 113 4: 674-685

Roberto J. C. Fonseca 1, Stephan-Nicollas M. C. G. Oliveira 1, Fábio R. Melo 1, Maria G. Pereira 2, Norma M. B. Benevides 2, Paulo A. S. Mourão1

Thromb Haemost 2008 99 3: 539-545